Kala Pharmaceuticals, Inc. announced that Gregory Grunberg, Managing Director at Longitude Capital, and Chen Yu, Managing Partner at Vivo Capital, joined as new Board members. Rajeev Shah, Managing Director and Portfolio Manager at RA Capital Management, joined the company's Board of Directors last year. Jonathan Silverstein, Partner and a Co-Head of Global Private Equity at OrbiMed, will hold a Board observer seat.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | 0.00% | -9.40% | -22.86% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
May. 14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.86% | 15.21M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals, Inc. Announces Board Appointments